The beneficial effects of Palm Tocotrienol Rich Fraction (TRF) in the reduction of cholesterol and oxidative stress in human especially in Non-Familial Hypercholesterolaemia (NFH) patients are still lacking and need to be further investigated. In this clinical trial, 37 NFH patients were recruited and randomized to either Palmvitee (60 mg/day TRF) [NFHe; n= 12) and atorvastatin 10 mg/day (NFHs; n=25). Fasting serum lipids, F2 -isoprostanes, oxidized LDL (ox-LDL) and malondialdehyde (MDA) were measured at baseline (BL), 2 weeks and 12 weeks. NFHe group showed significant reduction in Total cholesterol, TC, LDL, MDA, F2 – isoprostanes and ox-LDL at 12 weeks compared to BL. NFHs group showed a reduction in TC, LDL and TG, MDA and F2 – isoprostanes in 12 weeks compared to the BL. NFHs had greater % change reduction of TC, LDL, TG and MDA than NFHe in 12 weeks. Despite that, NFHe and NFHs had comparable % reduction of F2–isoprostanes in 12 weeks. NFHe had greater % change reduction of ox-LDL than NFHs. In conclusion, TRF reduces cholesterol level in NFH patients even though it is not as efficient as statins. The ability of TRF in the reduction of oxidative stress especially F2-isoprostanes is comparable with statins. TRF has a great potential in the prevention of atherosclerosis in part not only due to its cholesterol lowering activity, but perhaps more effective as a potent antioxidant.